- Trial phase
- Phase 1/2a
- Time to market
- A Phase 1/2a SAD portion is complete and the MAD portion is enrolling; assuming positive data, Phase 2/3 would likely follow. Commercial approval, if successful, is likely several years away (3+ years).
- Why 4/10
- No hard binary catalyst (PDUFA, pivotal readout) is scheduled in the next 12 months for ARO-DIMER-PA; the Phase 1/2a MAD data readout is the next major milestone but lacks a confirmed date. Arrowhead is now a commercial-stage company (REDEMPLO approved), so ARO-DIMER-PA is one of several pipeline assets rather than the sole value driver, capping the impact score at 4.
ARO-DIMER-PA delivered promising Phase 1 SAD data at AHA 2026, validating Arrowhead's dual-gene RNAi platform, but the stock is down 50% from its 52-week high amid institutional selling and pre-commercial cash-burn concerns. The next catalyst is the MAD portion data, which will test durability and safety of repeat dosing. With a mean analyst price target of $106 implying 122% upside, sentiment is bullish on the pipeline broadly, but no binary catalyst is imminent.
Price Chart
Executive Summary
ARO-DIMER-PA is Arrowhead Pharmaceuticals' investigational first-in-class dual-functional RNAi drug designed to silence both PCSK9 and APOC3 from a single injection, aiming to lower LDL cholesterol and triglycerides simultaneously in mixed hyperlipidemia. Phase 1 single-dose data presented at AHA 2026 showed 54-65% LDL reductions and 73-78% triglyceride reductions with one dose. The multiple ascending dose portion of the Phase 1/2a study is ongoing, with no imminent regulatory catalyst. Arrowhead is now a commercial-stage company with FDA-approved REDEMPLO, and analysts are bullish on the stock (mean PT $106, ~122% upside), though the stock has fallen sharply from its highs and faces cash-burn and competitive headwinds.
How It Works
ARO-DIMER-PA is a first-of-its-kind RNA interference (RNAi) drug that silences two genes (PCSK9 and APOC3) with a single molecule, using Arrowhead's TRiM delivery platform. PCSK9 is a protein that controls LDL (bad) cholesterol clearance; APOC3 is a protein that controls triglyceride metabolism. By targeting both at once from one injection, the drug aims to lower both LDL cholesterol and triglycerides simultaneously in patients with mixed hyperlipidemia at risk for cardiovascular disease.
Trial Status
Arrowhead completed the single ascending dose (SAD) portion of a Phase 1/2a randomized, double-blind, placebo-controlled trial. Interim topline data was announced September 15, 2026, showing mean maximal reductions in serum PCSK9 of 72% and APOC3 of 88% from a single dose. Updated results were presented at the American Heart Association Scientific Sessions on November 7, 2026, showing mean LDL cholesterol reductions up to 65% and median triglyceride reductions up to 78% with a single injection. The multiple ascending dose (MAD) portion of the trial is ongoing.
The Two-Sided Case
Upcoming Catalysts
- Phase 1/2a multiple ascending dose (MAD) data readout (date not yet announced)
- Initiation of Phase 2 or registrational trial planning, dependent on MAD results
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ARROWHEAD PHARMACEUTICALS, INC. 8-K ARWR ·Originating report